Specification setting for drugs in the pharmaceutical industry

被引:0
|
作者
Iwersen, Jorgen [1 ]
Melgaard, Henrik [1 ]
机构
[1] Novo Nordisk AS, Novo Alle, DK-2880 Bagsvaerd, Denmark
关键词
D O I
10.1007/3-7908-1687-6_15
中图分类号
T [工业技术];
学科分类号
08 ;
摘要
In the pharmaceutical industry a drug must conform to certain limits through its shelf life period. To ensure compliance in practice we need manufacturing processes to be robust and in control, measurements systems to be in control and the measurements must be traceable. Storage conditions must be under control. In this paper we discuss the practical implications involved in setting and maintaining specifications for drugs in the pharmaceutical industry. These include statistical process control limits, release limits, shelf life limits and in-use limits. The challenge here is to make this chain of limits consistent and at the same time be practical for use. The scientific approach to establishing a chain of specifications involves normal linear mixed models and an Arrhenius model, a kinetic model, describing e.g. the temperature dependence of drug degradation. These models are applied to data from stability studies as well as data from batch release.
引用
收藏
页码:249 / +
页数:3
相关论文
共 50 条
  • [31] Setting the scene The investigative toxicology landscape in the European pharmaceutical industry
    Roth, Adrian
    [J]. TOXICOLOGY LETTERS, 2017, 280 : S76 - S76
  • [32] THE POSITION OF THE PHARMACEUTICAL-INDUSTRY IN THE DEVELOPMENT OF DRUGS FOR PEDIATRIC USE
    CHRISTENSEN, CN
    [J]. PEDIATRIC PHARMACOLOGY, 1980, 1 (01): : 15 - 19
  • [33] Incentives and disincentives for research and development of new drugs by the pharmaceutical industry
    Curcio, Pasqualina Curcio
    [J]. CADERNOS DE SAUDE PUBLICA, 2008, 24 (10): : 2363 - 2375
  • [34] Risk/benefit evaluation of drugs: The role of the pharmaceutical industry in Germany
    Schosser, R
    [J]. EUROPEAN SURGICAL RESEARCH, 2002, 34 (1-2) : 203 - 207
  • [35] THE CONTRIBUTION OF THE PHARMACEUTICAL-INDUSTRY TO THE ARTICLES ON THE CLINICAL INVESTIGATION ON DRUGS
    LLOPIS, MCC
    [J]. MEDICINA CLINICA, 1995, 105 (19): : 758 - 758
  • [36] Advertising and competition in the ethical pharmaceutical industry: The case of antihypertensive drugs
    Risso, JA
    [J]. JOURNAL OF LAW & ECONOMICS, 1999, 42 (01): : 89 - 116
  • [37] How Basic Scientists Help the Pharmaceutical Industry Market Drugs
    Fugh-Berman, Adriane
    [J]. PLOS BIOLOGY, 2013, 11 (11)
  • [38] Pharmaceutical industry payments to physicians for the promotion of cancer drugs.
    Mitchell, Aaron Philip
    Meza, Akriti Mishra
    Trivedi, Niti U.
    Bach, Peter Brian
    Gonen, Mithat
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [39] Challenges and Gaps in Immunosafety Assessments of Pharmaceutical Drugs: An Industry Survey
    Collinge, M.
    Akella, S.
    Fogal, B.
    Fraser, K.
    Fuller, C. L.
    Harper, K. S.
    Jabbour, J.
    Maier, C. C.
    Malherbe, L.
    Marshall, N. B.
    Raman, K.
    Rao, G. K.
    Skaggs, H. S.
    Weber, F.
    Neff-LaFord, H.
    [J]. INTERNATIONAL JOURNAL OF TOXICOLOGY, 2022, 41 (01) : 72 - 72
  • [40] Substitutability Between Drugs, Innovation, and Fiscal Policy in the Pharmaceutical Industry
    de Mello-Sampayo, Felipa
    de Sousa-Vale, Sofia
    Camoes, Francisco
    [J]. ANNALS OF ECONOMICS AND FINANCE, 2015, 16 (02): : 273 - 289